NICE had previously reported that, if there is to be one, any Evaluation Consultation Document (ECD) (Note1) about eculizumab for aHUS would be released in the week commencing 17 February.
aHUSUK has been waiting to hear something all week and within the past hour has heard from NICE that Documentation release, following the Highly Specialised Technology Evaluation Committee meeting for Eculizumab on Wednesday 11 December 2013, has been delayed.
If an Evaluation Consultation Document (ECD) is produced, this will now be sent to consultees and commentators in the week commencing 24 February 2014.
NICE has previously said that if there is to be no ECD any Finally Evaluation Document,FED(Note 2),following would be issued in week commencing 10 March 2014.
The wait continues.
Notes extracted from NICE website
1. Evaluation consultation document (ECD) if produced
The Evaluation Committee make its provisional recommendations in the ECD. An ECD will be produced only if the recommendations from the Evaluation Committee are restrictive. A restrictive recommendation will be one that is more limited than the instructions for use that accompany the technology. Consultees and commentators have four weeks to comment on the ECD. The ECD is also made available on our website so health professionals and members of the public can comment on it.
2. Final evaluation determination (FED) produced
The Evaluation Committee considers the comments on the ECD if produced, then makes its final recommendations in the FED on how the technology should be used in the NHS in England. Consultees can appeal against the final recommendations in the FED.
Information about how NICE categorise their decisions can read by clicking here.